Cargando…

Antioxidative stress protein SRXN1 can be used as a radiotherapy prognostic marker for prostate cancer

PURPOSE: To explore the mechanisms of radiotherapy resistance and search for prognostic biomarkers for prostate cancer. METHODS: The GSE192817 and TCGA PRAD datasets were selected and downloaded from the GEO and UCSC Xena databases. Differential expression and functional annotation analyses were app...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xing, Yu, Jiandi, Wen, Huali, Yan, Junfeng, Peng, Kun, Zhou, Haiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507967/ https://www.ncbi.nlm.nih.gov/pubmed/37726767 http://dx.doi.org/10.1186/s12894-023-01319-1

Ejemplares similares

Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy
por: Wang, Xing, et al.
Publicado: (2022)

Association of SRXN1 Receptor Gene Polymorphism with Susceptibility to Periodontitis
por: Murthykumar, Karthikeyan, et al.
Publicado: (2022)

Beyond Antioxidant Activity: Redox Properties of Catechins May Affect Changes in the DNA Methylation Profile—The Example of SRXN1 Gene
por: Jakubek, Patrycja, et al.
Publicado: (2023)

SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling
por: Lv, Xiufang, et al.
Publicado: (2020)

CircABCA13 acts as a miR‐4429 sponge to facilitate esophageal squamous cell carcinoma development by stabilizing SRXN1
por: Luo, Junwen, et al.
Publicado: (2023)

Identification of SRXN1 and KRT6A as Key Genes in Smoking-Related Non-Small-Cell Lung Cancer Through Bioinformatics and Functional Analyses
por: Zhou, Jiazhen, et al.
Publicado: (2022)

Genetic Polymorphisms of Transcription Factor NRF2 and of its Host Gene Sulfiredoxin (SRXN1) are Associated with Cerebrovascular Disease in a Finnish Cohort, the TAMRISK Study
por: Kunnas, Tarja, et al.
Publicado: (2016)

At last, a predictive and prognostic marker for radiotherapy?
por: Coates, Philip, et al.
Publicado: (2010)

Evaluation of inflammatory cytokines and oxidative stress markers in prostate cancer patients undergoing curative radiotherapy
por: Abdel-Messeih, Phebe L., et al.
Publicado: (2017)

Fiducial markers in prostate cancer image-guided radiotherapy
por: Ghaffari, Hamed, et al.
Publicado: (2019)

Prognostic marker and target in prostate cancer
por: Lavorgna, Giovanni, et al.
Publicado: (2015)

The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas
por: Harat, Maciej, et al.
Publicado: (2019)

Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer
por: Liu, Jing-bo, et al.
Publicado: (2019)

Can the Adoption of Hypofractionation Guidelines Expand Global Radiotherapy Access? An Analysis for Breast and Prostate Radiotherapy
por: Irabor, Omoruyi Credit, et al.
Publicado: (2020)

Prognostic DNA Methylation Markers for Prostate Cancer
por: Strand, Siri H., et al.
Publicado: (2014)

Our experiences and suggestions with PEEK marker use in prostate cancer radiotherapy
por: Sen, Cenk Ahmet
Publicado: (2018)

Can circulating oxidative stress-related biomarkers be used as an early prognostic marker for COVID-19?
por: Uysal, Pelin, et al.
Publicado: (2023)

Prognostic Value of Sarcopenia and Systemic Inflammation Markers in Patients Undergoing Definitive Radiotherapy for Esophageal Cancer
por: Liang, Huanwei, et al.
Publicado: (2021)

Prognostic Factors in Postoperative Radiotherapy for Prostate Cancer – Tertiary Center Experience
por: Miszczyk, Marcin, et al.
Publicado: (2021)

Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study
por: Chen, Baoqing, et al.
Publicado: (2019)

Antioxidative effects of hesperetin against lead acetate-induced oxidative stress in rats
por: Wang, Jicang, et al.
Publicado: (2013)

Microvessel density as new prognostic marker after radiotherapy in rectal cancer
por: Svagzdys, Saulius, et al.
Publicado: (2009)

Effectiveness and cost-effectiveness of prognostic markers in prostate cancer
por: Calvert, N W, et al.
Publicado: (2003)

Prognostic comparison between radical prostatectomy and radiotherapy in prostate cancer patients at different stages and ages
por: Wang, Fei, et al.
Publicado: (2021)

Transcriptomic responses to drought stress in Polygonatum kingianum tuber
por: Qian, Huali, et al.
Publicado: (2021)

Can pelvic radiotherapy induce a leiomyosarcoma of the prostate? (A case report)
por: Bkiri, Saad, et al.
Publicado: (2022)

Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
por: Loh, Jasmin, et al.
Publicado: (2015)

Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality imaging
por: Osman, Sarah O. S., et al.
Publicado: (2019)

Prostate deformation during hypofractionated radiotherapy: an analysis of implanted fiducial marker displacement
por: Knybel, Lukas, et al.
Publicado: (2021)

Prognostic nutritional index serves as a predictive marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2016)

Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015)

Prognostic significance of lymphovascular invasion in patients with prostate cancer treated with postoperative radiotherapy
por: Jeong, Jae-Uk, et al.
Publicado: (2019)

Can Mean Platelet Volume Serve as a Marker for Prostatitis?
por: Karaman, Hatice, et al.
Publicado: (2013)

Can nutrition interventions tackle the global insulin affordability via improving diabetes management and reducing insulin demand?
por: Lu, Victoria, et al.
Publicado: (2022)

Volumetric‐based image guidance is superior to marker‐based alignments for stereotactic body radiotherapy of prostate cancer
por: Li, Wen, et al.
Publicado: (2018)

MUC1 as a Putative Prognostic Marker for Prostate Cancer
por: Strawbridge, Rona J, et al.
Publicado: (2008)

Mast Cells as a Potential Prognostic Marker in Prostate Cancer
por: Taverna, Gianluigi, et al.
Publicado: (2013)

Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer
por: Burdelski, Christoph, et al.
Publicado: (2014)

Immune-Related Genes Are Prognostic Markers for Prostate Cancer Recurrence
por: Fu, Min, et al.
Publicado: (2021)

Intraprostatic fiducial markers: a potential application for ultrasound-guided radiotherapy in prostate cancer
por: Vavassori, A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_okkcme49hdf0et74g4a1q9vbhs